• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Roberto Chiarle, MD


  • Gostissa M, Schwer B, Chang A, Dong J, Meyers RM, Marecki GT, Choi VW, Chiarle R, Zarrin AA, Alt FW.IgH class switching exploits a general property of two DNA breaks to be joined in cis over long chromosomal distances.Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2644-9.
  • Semrau S, Crosetto N, Bienko M, Boni M, Bernasconi P, Chiarle R, van Oudenaarden A.FuseFISH: robust detection of transcribed gene fusions in single cells.Cell Rep. 2014 Jan 16;6(1):18-23.
  • Chiarle R.Translocations in normal B cells and cancers: insights from new technical approaches.Adv Immunol. 2013;117:39-71.
  • Crosetto N, Mitra A, Silva MJ, Bienko M, Dojer N, Wang Q, Karaca E, Chiarle R, Skrzypczak M, Ginalski K, Pasero P, Rowicka M, Dikic I.Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing.Nat Methods. 2013 Apr;10(4):361-5.
  • Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M.FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.Nature. 2012 Jan 5;481(7379):90-3.
  • Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Gostissa M, Alt FW.Genome-wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells.Cell. 2011 Sep 30;147(1):107-19.
  • Gostissa M, Alt FW, Chiarle R.Mechanisms that Promote and Suppress Chromosomal Translocations in Lymphocytes.Annu Rev Immunol. 2011 Apr 23;29:319-50.
  • Chiarle R, Martinengo C, Mastini C, Ambrogio C, D'Escamard V, Forni G, Inghirami G.The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.Nat Med. 2008 Jun;14(6):676-80.
  • Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G.The anaplastic lymphoma kinase in the pathogenesis of cancer.Nat Rev Cancer. 2008 Jan;8(1):11-23. Review.
  • Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, Karras JG, Levy DE, Inghirami G.Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target.Nat Med. 2005 Jun;11(6):623-9.